| INTRODUC TI ON
Immunophenotyping is an essential tool in the diagnostic work-up and classification of hematological malignancies. It has provided crucial information for the diagnosis, classification, and monitoring of hematological malignancies.
1 Acute myeloid leukemia (AML) is a heterogeneous bone marrow malignancy, and cases with the t (8;21) translocation represent a subset with specific clinical and biological characteristics. The prognosis is better for these patients than for the majority of AML patients. 2 Molecular (cyto)genetics is regarded as the gold standard for diagnosis. However, due to the variety of genetic abnormalities involved in AML and AML-related progenitor cell tumors, comprehensive screening has been difficult because of the economic burden at present. Therefore, to discriminate t (8;21) AML from other subtypes of AML promptly and accurately, relevant molecular (cyto)genetic examination is crucial. 3 Previously, identification of the generally indicative morphology has been hindered by strong subjectivity and poor sensitivity. Therefore, this study strived to distinguish AML early using flow cytometry (FC), aiming to provide direction for subsequent genetic examination. 
| Criteria for evaluation of outcomes
The threshold for positivity was based generally on isotype and internal negative controls. The expression intensity of CD34 was judged by the expression intensity of the normal blasts. The positivity threshold was 20% for membrane antibody 6 and 10% for cytoplasmic antibody. Fisher's exact test for dichotomous data. P < 0.05 was considered to be statistically significant. Producing a point for each of these six FC features, an FC score was constructed that could be used to predict which cases were likely to possess the t(8;21) translocation. Figure 3 shows this ROC curve. In ROC analysis, a perfect screening test would achieve an area under the curve (AUC) of 1, while a test no better than random guessing would achieve an AUC of 0.5. This score has an AUC of 0.952, suggesting that this score has a satisfactory discriminatory value for identification of t(8;21) AML. Table 2 lists a series of values of the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of this scoring system, indicating that when the cutoff value was set at 3, its sensitivity was 0.86 and specificity was 0.90, both of which were relatively high.
| RE SULTS

| Development of a t(8;21) AML FC score
This histogram (Figure 4 ) directly reflects the distribution of t(8;21) AML and AML with maturation in this scoring system. Most cases with t(8;21) AML were distributed among 3-5 points, while cases with AML with maturation mostly distributed to 0-1 point and were found absent above 4 points.
| Validation of the t(8;21) AML FC score
In order to confirm the utility of this FC score in the distinction of t(8;21) AML from the majority of AML cases, the score was prospec- females aged 0-81 years; not including AML-M6 and M7). As can be seen in Figure 5 , the AUC of the ROC curve for this validation cohort was 0.975, similar to that of the derivation cohort. 
| D ISCUSS I ON
The t(8;21) abnormality is found in approximately 5%-10% of all AML cases. [9] [10] [11] [12] [13] [14] Its early screening and diagnosis are essential for predicting prognosis, guiding treatment, and monitoring minimal residual disease (MRD). Molecular (cyto)genetics is regarded as the gold standard for this diagnosis and also plays an important role in risk stratification, therapy, and minimal residual detection. [15] [16] [17] [18] [19] [20] However, different subtypes of AML have different genetic abnormalities; yet for the reason of limited medical cost, comprehensive screening for all of these abnormalities is difficult. This is especially true for some gene mutations, such as the c-Kit mutation, which is closely related to prognostic stratification of the core-binding factor AML such as in t(8;21) AML [21] [22] [23] but is sometimes ignored due to limited medical resources in our country.
For more than two decades, flow cytometry has played an essential role in the diagnosis and classification of acute leukemia. 24, 25 Specific immunophenotypic profiles have been associated with prognosis and/or unique molecular (cyto)genetic abnormalities. [26] [27] [28] [29] [30] [31] In addition, MRD detection by multiparametric flow cytometry (MFC) has proven useful to predict relapse and poor outcome in AML patients. [32] [33] [34] [35] [36] Due to the fact that RUNX1-RUNX1T1 transcripts can persist in patients with t(8;21) even after stem-cell transplantation with GVHD and in long-time CR, 37-41 exclusive detection of the fusion gene may lead to the decline of specificity for diagnosis of MRD. Therefore, determination of MRD levels according to LAIP (leukemia-associated immunophenotypes), which is applicable to the majority of AML patients, can lead to more accurate results and prediction of clinical outcomes in a consistent manner.
35,42
Many studies have elaborated the immunophenotypic characteristics of AML with t(8;21) (q22; q22); RUNX1-RUNX1T1. Meanwhile, in this study, characteristics including maturity disturbance of granulocytes and co-expression of CD56 in neutrophils were highlighted, which have received less attention in previous studies. 4, 8 The occurrence rate of these two In conclusion, we present data here suggesting that when differentiating t(8;21) AML from the majority of AML cases, the greatest weight should be given to high-intensity expression of CD34 and aberrant expression of the lymphoid markers CD19, cytoplasmic CD79a, and CD56 in myeloblasts; co-expression of CD56 in neutrophils, especially in immature neutrophils; and maturity disturbance of granulocytes. Furthermore, over three points of these six features above could allow a sensitivity of 86%-91% of t (8; 21) AML diagnosis (Tables 2 and 3 ). The more points it gets, the higher probability it is t 
